Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
Niklas Mattsson(Malmö University), Oskar Hansson(Eli Lilly (United States)), Sebastian Palmqvist(Skåne University Hospital), Rik Ossenkoppele(Malmö University), Erik Stomrud(Lund University), Kaj Blennow(Sahlgrenska University Hospital), Pontus Tideman(Lund University), Erin M. Jonaitis(University of Wisconsin–Madison), Karly Alex Cody(Stanford University), Gemma Salvadó(Lund University), Henrik Zetterberg(University of Wisconsin–Madison), Sterling C. Johnson(Wisconsin Society for Cardiovascular and Pulmonary Health & Rehabilitation), Shorena Janelidze(Lund University), Nicholas J. Ashton(King's College London), Rebecca Langhough(University of Wisconsin–Madison), Tobey J. Betthauser(University of Wisconsin–Madison)
Cited by 293
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k